Asset Details
Do you wish to reserve the book?
Urine epidermal growth factor as a biomarker for kidney function recovery and prognosis in glomerulonephritis with severe kidney function impairment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Urine epidermal growth factor as a biomarker for kidney function recovery and prognosis in glomerulonephritis with severe kidney function impairment
Do you wish to request the book?
Urine epidermal growth factor as a biomarker for kidney function recovery and prognosis in glomerulonephritis with severe kidney function impairment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Urine epidermal growth factor as a biomarker for kidney function recovery and prognosis in glomerulonephritis with severe kidney function impairment
2024
Overview
Background
Prognostication in glomerulonephritis with severe kidney function impairment is critical for evaluating the benefit-to-risk ratio of immunosuppression. We hypothesized that the urine biomarker epidermal growth factor (EGF) could have good discrimination power to identify subjects who might ultimately recover kidney function.
Methods
We included 82 subjects with glomerulonephritis and severe kidney function impairment at admission (estimated glomerular filtration rate [eGFR] ≤ 30 mL/min/1.73m
2
): 58 with lupus nephritis (LN) and 24 with ANCA-associated vasculitis (AAV). Thirty-five subjects required kidney replacement therapy (KRT) at presentation. Urine epidermal growth factor was measured and corrected by urine creatinine (uEGF/Cr) and the population was analyzed by uEGF/Cr tertiles. The primary outcome was time to recovery of eGFR ≥ 30 mL/min/1.73m
2
and time to recovery of kidney function with dialysis independence in those with initial KRT.
Results
Forty-four (54%) participants met the primary outcome of recovery of eGFR ≥ 30 mL/min/1.73m
2
. The 6-month recovery rates were 93%, 57%, and 0% for participants in the highest, middle, and lowest uEGF/Cr tertile, respectively. Recovery of the kidney function was faster and led to a higher post-therapy eGFR in the highest uEGF/Cr tertile. In the ROC analysis, uEGF/Cr was a predictor of recovery with an area under the curve (AUC) of 0.92 (95% CI 0.87–0.98), and a cutoff of 2.60 ng/mg had 100% sensitivity to detect patients who recovered kidney function. In the subgroup of participants with initial KRT, the cut-off of uEGF/Cr of 2.0 ng/mg had 100% sensitivity to detect participants who recovered kidney function with dialysis independence by 6 months.
Conclusions
Urine EGF/Cr is a promising biomarker to aid in the prediction of recovery of kidney function in glomerulonephritis with severe kidney function impairment.
Graphical abstract
Publisher
Springer International Publishing,Oxford University Press
Subject
/ Aged
/ Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - complications
/ Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - diagnosis
/ Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - physiopathology
/ Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - urine
/ Biobanks
/ Biopsy
/ Epidermal Growth Factor - urine
/ Etiology
/ Female
/ Glomerulonephritis - complications
/ Glomerulonephritis - diagnosis
/ Glomerulonephritis - physiopathology
/ Humans
/ Lupus
/ Lupus Nephritis - complications
/ Lupus Nephritis - physiopathology
/ Male
/ Medicine
/ Urine
/ Urology
